CCR2-64I and CXCL12 3′A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy

This publication has 25 references indexed in Scilit:

• Associations of CCR5, CCR2, and Stromal Cell–Derived Factor 1 Genotypes with Human Immunodeficiency Virus Disease Progression in Patients Receiving Nucleoside Therapy
  The Journal of Infectious Diseases, 2001
• Effects of CCR5-Δ 32, CCR2-64I, and SDF-1 3′A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data
  Annals of Internal Medicine, 2001
• CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response
  AIDS, 2001
• CCR5 Δ32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients
  AIDS, 2000
• Shorter Survival ofSDF1‐3′A/3′AHomozygotes Linked to CD4⁺T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection
  The Journal of Infectious Diseases, 2000
• Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment
  AIDS, 1998
• CCR5 promoter polymorphism and HIV-1 disease progression
  The Lancet, 1998
• The role of a mutant CCR5 allele in HIV–1 transmission and disease progression
  Nature Medicine, 1996
• Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene
  Science, 1996
• Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection
  Cell, 1996